BioSpace News Archive

Chemomab Therapeutics Ltd. today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023.

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited financial results for the first quarter ended March 31, 2023, and provided corporate and portfolio updates.

Syndax Pharmaceuticals, Inc. today announced that members of its management team will participate in two upcoming investor conferences.

Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial in the U.S. Endo will commercialize the FDA-approved product through its Par Sterile Products business and expects to begin shipping in summer 2023.

Kyverna Therapeutics today announced it will present new preclinical findings on KYV-101. KYV-101 is a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy designed to deplete B cells, including autoreactive B cells in autoimmune disease patients.

EDAP TMS SA, the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Healthcare Conference, which is being held June 7-9, 2023, in New York City.

Centessa Pharmaceuticals plc today announced that members of its management team will participate in the following investor conferences.

Mersana Therapeutics, Inc. today announced that members of management will present at the following upcoming investor conferences.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced today the presentation of updates on the development of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the Vaccines Summit Boston 2023 and the Congress for the International Society for the Advancement of Cytometry (CYTO) 2023 meetings.

Nautilus Biotechnology, Inc. today announced the company will be participating in the following investor conferences.